Bosutinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukaemia: results from the 24‐month follow‐up of the BELA trial-Reference-Cited by-同舟云学术

Bosutinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukaemia: results from the 24‐month follow‐up of the BELA trial

Published:2014-09-08 Issue:1 Volume:168 Page:69-81
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Brümmendorf Tim H.¹²,Cortes Jorge E.³,Souza Cármino Antonio⁴,Guilhot Francois⁵,Duvillié Ladan⁶,Pavlov Dmitri⁷,Gogat Karïn⁶,Countouriotis Athena M.⁸,Gambacorti‐Passerini Carlo⁹

Affiliation:

1. Universitätsklinikum Aachen RWTH Aachen Aachen Germany

2. Universitätsklinikum Hamburg‐Eppendorf Hamburg Germany

3. The University of Texas MD Anderson Cancer Center Houston TX USA

4. University of Campinas Campinas SP Brazil

5. Inserm CIC 1402 CHU de Poitiers Poitiers France

6. Pfizer Global Research and Development Paris France

7. Pfizer New York NY USA

8. Pfizer La Jolla CA USA

9. University of Milano‐Bicocca Monza Italy

Funder

Pfizer

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.13108

Reference37 articles.

1. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

2. Inhibitory effect of imatinib on normal progenitor cells in vitro

3. Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

4. Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

5. Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Choice of Frontline Tyrosine‐Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A “Campus CML” Study;European Journal of Haematology;2024-09-12

2. Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data;Cancer Medicine;2024-09

3. Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia;Frontiers in Oncology;2024-08-26

4. Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia;Annals of Hematology;2024-07-18

5. Chronic myeloid leukaemia: Biology and therapy;Blood Reviews;2024-05